Interim Report for the period January – September 2020
An additional Phase 3 study in Alzheimer’s diseaseKey events during the third quarter 2020 · BioArctic’s partner Eisai has started an additional global clinical Phase 3 program (AHEAD 3-45) to evaluate the effect of BAN2401 in individuals who have not yet developed symptoms of Alzheimer’s disease but have intermediate or elevated amyloid levels in the brain. · Eisai presented new data regarding BAN2401 from the open-label extension study at the Alzheimer’s Association International Conference® (AAIC). The data indicated a rapid and continual reduction in amyloid levels in the brain
